Chapter 2 Antipsychotic Agents and Dopamine Agonists

John McDermed, Richard J. Miller

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This chapter summarizes the effective results of neuroleptic (antipsychotic) drugs in symptomatic treatment of schizophrenia, whose etiologies are unknown and may not be identical. This review begins with the recent discoveries about dopamine (DA) receptors. From the identification of DA receptors at the biochemical level, it has become clear that heterogeneity of DA receptors exists. Kainic acid injection into the striatum destroys striatal neurons, on which postsynaptic DA receptors are located while sparing axons that pass through this region and terminals that end within it. The bovine parathyroid gland is a tissue with a relatively homogeneous population of D-1 (cyclase-linked) receptors. In this tissue, DA stimulates the accumulation of cyclic adenosine monophosphate (c-AMP) and this event is followed by the release of parathyroid hormone from the gland. Apomorphine (APO) acts as a pure antagonist in this system. It appears that haloperidol and the other classical neuroleptics block both types of DA receptors. It is a corollary of the DA hypothesis of schizophrenia that pharmacological screening methods for antipsychotics are usually designed to discover DA blocking agents. Neuroleptics typically increase DA turnover, elevate prolactin levels, compete with DA receptor ligands for membrane binding sites, induce catalepsy, and block conditioned avoidance responding (CAR) in trained animals. Amoxapine that was previously known as a clinically effective antidepressant has now been shown by a Lederle group to have significant neuroleptic activity in a number of animal models. Nomifensin is an antidepressant that produces significant DA-mimetic motor effects in animal models. The ergot alkaloids have generally complex pharmacological profiles, but some with DA agonist properties are therapeutically useful.

Original languageEnglish (US)
Pages (from-to)12-21
Number of pages10
JournalAnnual Reports in Medicinal Chemistry
Volume14
Issue numberC
DOIs
StatePublished - Jan 1 1979

Fingerprint

Dopamine Agonists
Dopamine Receptors
Antipsychotic Agents
Dopamine
Animals
Parathyroid Glands
Antidepressive Agents
Schizophrenia
Amoxapine
Animal Models
Pharmacology
Nomifensine
Ergot Alkaloids
Tissue
Catalepsy
Corpus Striatum
Dopamine Agents
Apomorphine
Kainic Acid
Haloperidol

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry

Cite this

@article{551e8226c48241b2a75a29fc82601cb3,
title = "Chapter 2 Antipsychotic Agents and Dopamine Agonists",
abstract = "This chapter summarizes the effective results of neuroleptic (antipsychotic) drugs in symptomatic treatment of schizophrenia, whose etiologies are unknown and may not be identical. This review begins with the recent discoveries about dopamine (DA) receptors. From the identification of DA receptors at the biochemical level, it has become clear that heterogeneity of DA receptors exists. Kainic acid injection into the striatum destroys striatal neurons, on which postsynaptic DA receptors are located while sparing axons that pass through this region and terminals that end within it. The bovine parathyroid gland is a tissue with a relatively homogeneous population of D-1 (cyclase-linked) receptors. In this tissue, DA stimulates the accumulation of cyclic adenosine monophosphate (c-AMP) and this event is followed by the release of parathyroid hormone from the gland. Apomorphine (APO) acts as a pure antagonist in this system. It appears that haloperidol and the other classical neuroleptics block both types of DA receptors. It is a corollary of the DA hypothesis of schizophrenia that pharmacological screening methods for antipsychotics are usually designed to discover DA blocking agents. Neuroleptics typically increase DA turnover, elevate prolactin levels, compete with DA receptor ligands for membrane binding sites, induce catalepsy, and block conditioned avoidance responding (CAR) in trained animals. Amoxapine that was previously known as a clinically effective antidepressant has now been shown by a Lederle group to have significant neuroleptic activity in a number of animal models. Nomifensin is an antidepressant that produces significant DA-mimetic motor effects in animal models. The ergot alkaloids have generally complex pharmacological profiles, but some with DA agonist properties are therapeutically useful.",
author = "John McDermed and Miller, {Richard J.}",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/S0065-7743(08)61347-0",
language = "English (US)",
volume = "14",
pages = "12--21",
journal = "Annual Reports in Medicinal Chemistry",
issn = "0065-7743",
publisher = "Academic Press Inc.",
number = "C",

}

Chapter 2 Antipsychotic Agents and Dopamine Agonists. / McDermed, John; Miller, Richard J.

In: Annual Reports in Medicinal Chemistry, Vol. 14, No. C, 01.01.1979, p. 12-21.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chapter 2 Antipsychotic Agents and Dopamine Agonists

AU - McDermed, John

AU - Miller, Richard J.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - This chapter summarizes the effective results of neuroleptic (antipsychotic) drugs in symptomatic treatment of schizophrenia, whose etiologies are unknown and may not be identical. This review begins with the recent discoveries about dopamine (DA) receptors. From the identification of DA receptors at the biochemical level, it has become clear that heterogeneity of DA receptors exists. Kainic acid injection into the striatum destroys striatal neurons, on which postsynaptic DA receptors are located while sparing axons that pass through this region and terminals that end within it. The bovine parathyroid gland is a tissue with a relatively homogeneous population of D-1 (cyclase-linked) receptors. In this tissue, DA stimulates the accumulation of cyclic adenosine monophosphate (c-AMP) and this event is followed by the release of parathyroid hormone from the gland. Apomorphine (APO) acts as a pure antagonist in this system. It appears that haloperidol and the other classical neuroleptics block both types of DA receptors. It is a corollary of the DA hypothesis of schizophrenia that pharmacological screening methods for antipsychotics are usually designed to discover DA blocking agents. Neuroleptics typically increase DA turnover, elevate prolactin levels, compete with DA receptor ligands for membrane binding sites, induce catalepsy, and block conditioned avoidance responding (CAR) in trained animals. Amoxapine that was previously known as a clinically effective antidepressant has now been shown by a Lederle group to have significant neuroleptic activity in a number of animal models. Nomifensin is an antidepressant that produces significant DA-mimetic motor effects in animal models. The ergot alkaloids have generally complex pharmacological profiles, but some with DA agonist properties are therapeutically useful.

AB - This chapter summarizes the effective results of neuroleptic (antipsychotic) drugs in symptomatic treatment of schizophrenia, whose etiologies are unknown and may not be identical. This review begins with the recent discoveries about dopamine (DA) receptors. From the identification of DA receptors at the biochemical level, it has become clear that heterogeneity of DA receptors exists. Kainic acid injection into the striatum destroys striatal neurons, on which postsynaptic DA receptors are located while sparing axons that pass through this region and terminals that end within it. The bovine parathyroid gland is a tissue with a relatively homogeneous population of D-1 (cyclase-linked) receptors. In this tissue, DA stimulates the accumulation of cyclic adenosine monophosphate (c-AMP) and this event is followed by the release of parathyroid hormone from the gland. Apomorphine (APO) acts as a pure antagonist in this system. It appears that haloperidol and the other classical neuroleptics block both types of DA receptors. It is a corollary of the DA hypothesis of schizophrenia that pharmacological screening methods for antipsychotics are usually designed to discover DA blocking agents. Neuroleptics typically increase DA turnover, elevate prolactin levels, compete with DA receptor ligands for membrane binding sites, induce catalepsy, and block conditioned avoidance responding (CAR) in trained animals. Amoxapine that was previously known as a clinically effective antidepressant has now been shown by a Lederle group to have significant neuroleptic activity in a number of animal models. Nomifensin is an antidepressant that produces significant DA-mimetic motor effects in animal models. The ergot alkaloids have generally complex pharmacological profiles, but some with DA agonist properties are therapeutically useful.

UR - http://www.scopus.com/inward/record.url?scp=77957121431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957121431&partnerID=8YFLogxK

U2 - 10.1016/S0065-7743(08)61347-0

DO - 10.1016/S0065-7743(08)61347-0

M3 - Article

VL - 14

SP - 12

EP - 21

JO - Annual Reports in Medicinal Chemistry

JF - Annual Reports in Medicinal Chemistry

SN - 0065-7743

IS - C

ER -